Abstract: The increased interest in nanomedicine and its applicability for a wide range of biological functions demands the search for raw materials to create nanomaterials. Recent trends have focused on the use of green chemistry to synthesize metal and metal-oxide nanoparticles. Bioactive chemicals have been found in a variety of marine organisms, including invertebrates, marine mammals, fish, algae, plankton, fungi, and bacteria. These marine-derived active chemicals have been widely used for various biological properties. Marine-derived materials, either whole extracts or pure components, are employed in the synthesis of nanoparticles due to their ease of availability, low cost of production, biocompatibility, and low cytotoxicity toward eukaryotic cells. These marine-derived nanomaterials have been employed to treat infectious diseases caused by bacteria, fungi, and viruses as well as treat non-infectious diseases, such as tumors, cancer, inflammatory responses, and diabetes, and support wound healing. Moreover, a variety of pure bioactive compounds have been loaded onto polymeric nanocarriers and employed to treat infectious and non-infectious diseases. The current review is focused on a thorough overview of nanoparticle synthesis and its biological applications made from their entire extracts or pure chemicals derived from marine sources.

Keywords: marine; nanoparticles; infectious disease; antimicrobial; anticancer; antioxidant; antiinflammatory; antidiabetic

1. Introduction

Infectious diseases have the potential to contribute to an increase in the global death rate [1]. Infectious diseases can be caused by viruses, fungi, and bacteria [2]. These microorganisms cause a variety of diseases, including cholera, candidiasis, and COVID-19 [3,4]. COVID-19 is a recent example that has triggered a pandemic [5]. Multiple drug resistance in viruses, fungi, and bacteria has reached alarming levels that must be addressed promptly. Various health organizations throughout the world have stated that various drug-resistant pathogenic microorganisms must be eradicated quickly [6]. Furthermore, current drugs for treating infectious diseases to patients suffering from non-infectious illnesses, such as cancer, inflammation, obesity, and diabetes, might possibly harm the human body [7–9]. To meet this demand, novel molecules that can function as antimicrobials against pathogenic microbes must be investigated [10]. The terrestrial ecosystem has yet to investigate the...
marine environment [11]. Many applications for marine compounds have been documented [12]. Secondary metabolites produced by marine microorganisms have a wide range of applications [13]. The potential biological activity of marine organisms stems from communication and defensive systems in their natural habitat [13]. Many possible antimicrobial applications from marine sources have been investigated [14].

Furthermore, due to their biodiversity and production of various molecules with varying chemical structures, marine organisms can be exploited as valuable biologics to treat cancer, inflammation, and immune system diseases [15]. As a result of their diverse biological activities, natural compounds derived from marine resources have significantly contributed to disease treatment in place of conventional pharmaceuticals [16]. Nanotechnology is a developing technology with several applications in various sectors [17]. Recent research trends have demonstrated that nanoparticles have a wide range of therapeutic potential [18]. The biosynthesis of nanoparticles is a simple and inexpensive method [19]. Furthermore, the approach of synthesizing nanoparticles from diverse natural products is extensively employed as an eco-friendly method, since it does not produce toxic by-products [20]. Various techniques have been developed to synthesize different types of inorganic nanoparticles, such as gold, zinc, titanium, magnesium, and silver [21]. The biosynthesis of nanoparticles provides antibacterial, drug delivery, sensing, and anticancer treatment. Nanoparticles produced from pure compounds, in particular, outperform traditional drugs in terms of biological activity [22]. This review paper advances our understanding of marine-derived compound nanoparticles as possible therapeutics for a variety of biological roles.

2. Green Synthesis of Nanoparticles (NPs) for Its Application in the Field of Medicine

Nanotechnology is a new discipline of research that works with chemical, biological, and physical sciences to produce nanosized particles with various applications. The size range of nanoparticles has been investigated between 1–100 nm [23–25]. Because of their high surface area to volume ratio, nanoparticles have a substantially larger proportion of surface, which leads to enhanced reactivity [26]. Because of their small size, nanoparticles can have a variety of sizes and forms [27]. Nanoparticles have a wide range of applications, including the medicinal, diagnostic, drug discovery, biological sensor, and reagent industries [28]. These biologically active nanoparticles are produced by employing various biological fluids as reducing agents for metal and non-metal ions, such as gold, silver, copper, zinc oxide, platinum, and titanium oxide [29]. The diverse therapeutic applications of nanoparticles, as well as the outbreak of several infectious diseases, motivate this research [30]. The general approaches for nanoparticle production include bioassisted, chemical, and physical methods [31]. Researchers are currently more interested in biological entities than chemical approaches. Fungi, bacteria, plants, and algae from the marine have been found to produce nanoparticles [12]. Green synthetic nanoparticles can be easily decomposed using enzymes included in the nanoparticles, making them more environmentally benign than conventional agents [29]. The reduction of metal ions by reducing agents found in the organism is essential for the synthesis of metal nanoparticles [32]. These reactions are driven by phenolics, terpenoids, alkaloids, amines, carbonyl groups, flavanones, proteins, pigments, and amides found in the organism [33]. Because marine organisms dwell on the unexplored seabed, it is critical to understand the metabolic mechanisms leading to metal ion reduction by diverse types of marine organisms [33]. Figure 1 depicts the different marine organisms, such as algae, bacteria, fungi, and animals, employed in the synthesis of metal nanoparticles.
3. Marine Organisms and Compounds for the Green Synthesis of NPs

Current research and innovation in marine science are contributing to the exponential growth of numerous sectors, including pharmaceuticals, environmental trends, nanomedicine, and food [14]. The ocean covers around 70–71% of the earth’s surface [34]. Previous research studied the oceans, accounting for around 2.2 million distinct species [35]. The ocean contains an unimaginable number of marine-derived compounds with varied applications that are beneficial to humans, such as antimicrobial compounds [36]. The marine ecosystem contains around 25,000 physiologically active chemicals with various applications [37]. Currently, the marine environment paves the way for numerous antibacterial, antifungal, and antiviral compounds. Seaweeds, bacteria, and fungus are possible sources for combating infectious diseases [14,38]. According to prior research, the market for marine-derived compounds has surpassed 10 billion USD [39]. The production of marine-based nanoparticles from a variety of sources, including bacteria, fungus, seaweeds, and marine plants, has received considerable attention [33]. Algae with high cell growth rates, high stress tolerance, and an abundance of physiologically active substances, such as Ulva lactuca, Spirulina platensis, and Sargassum muticum, are regarded as promising biocatalysts for the synthesis of various types of nanomaterials [40–42]. Among pure algal compounds, phloroglucinol, eckol, chlorofucofuroeckol A, fucodiphlorethol G, 7′-phloroeckol, 6,6′-dieckol, and dieckol act as effective reducing agents in the nanoparticle synthesis process [43]. Diverse marine microorganisms adapt to harsh marine environments as well as a broad variety of temperatures, salinity, and pH, making them suitable biological factories for green nanoparticle synthesis [44]. Bacteria and fungi produce intracellular or extracellular inorganic compounds that react with metal ions to form nanoparticles [45,46]. Furthermore, nanoparticles made from marine-derived animals show good biocompatibility [47]. Seafood waste, in particular, may be used to make a variety of biological products by utilizing its high value-added qualities during the purification process [48]. Figure 2 shows numerous pure compounds obtained from marine organisms that act as reducing agents in the nanoparticle synthesis process.
4. Marine Bioinspired NPs Used for Bacterial Infection

Table 1 summarizes a detailed review of marine-based nanoparticles utilized in treating various infectious diseases. Bacterial infection has a negative impact on public health [49]. Nanoparticles are attractive options since they have excellent bactericidal activity when treating pathogenic bacteria [50]. Several studies have been carried out to investigate the mechanisms of marine-inspired nanoparticles as antibacterial agents [51]. In general, marine antimicrobial macromolecules exhibit antibacterial mechanisms, such as (1) inhibition of DNA replication, (2) inhibition of expression of enzymes and other cellular proteins required for ATP production, (3) structural changes and damage to bacterial cell membranes, and (4) ROS production by inhibiting respiratory enzymes [52]. Several marine bacteria, including Vibrio spp., Pseudoalteromonas spp., and Ruegeria spp., generate antimicrobial compounds, a feature seen globally [53]. The marine bacterium Pseudomonas rhizospherae, in particular, has been shown to produce benzene-type secondary metabolites with potent antibacterial properties [54]. Secondary metabolites produced by marine algae, on the other hand, include polyphenols, terpenes, acetogenin, and aromatic compounds, which have a variety of biological functions, including antibacterial effects [55]. Silver nanoparticles derived from the marine cyanobacterium Chroococcus minutus showed antibacterial action against pathogenic strains of Escherichia coli and Streptococcus pyogenes, which have been discovered to be novel antibacterial for upper respiratory tract infection [56]. The synthesis of silver nanoparticles from cyanobacterium sources had improved control over pathogenic bacteria. Silver nanoparticles derived from the marine endophytic fungus Penicillium polonicum showed antibacterial activity against Acinetobacter baumanii, with MIC value of 15.62 µg/mL and MBC value of 31.24 µg/mL [44]. These findings were attributed to the activation of apoptosis by altering the osmotic pressure regulation of cells during the interaction of silver nanoparticles and bacteria. Silver nanoparticles using S. muticum extracts as a capping agent significantly suppressed the growth of Bacillus subtilis, E. coli, Klebsiella pneumoniae, and Salmonella Typhimurium [57]. These silver nanoparticles interacted with the bacterial membrane and penetrated the bacterium. Moreover, silver nanoparticles synthesized using S. swartzii showed antibacterial action by producing considerable deteri-
oration in *E. coli* [58]. When combined with silver nanoparticles, *S. wightii* and *Valonopsis pachynema* demonstrated increased antibacterial activity against *Micrococcus luteus* and *S. marcescens* [59]. Silver nanoparticles produced from these seaweeds had a strong antibacterial activity because silver ions caused bacteria to release K⁺ ions. Silver nanoparticles produced from an aqueous extract of *Gelidiella acerosa* inhibited the growth of *P. aeruginosa* and *B. subtilis* [60]. These bacteria were discovered to absorb silver nanoparticles from the cell surface. Silver nanoparticles produced using a culture-free extract of marine *Streptomyces* sp. Al-Dhabi-87 had excellent antibacterial activity against wound-infecting microorganism strains such as *Staphylococcus aureus*, *S. epidermidis*, and *Enterococcus faecalis* [61]. These nanoparticles displayed antibacterial action by releasing intracellular components and altering the cellular structure. Secondary metabolites found in *S. longifolium* extract reduced CuSO₄ to Cu²⁺, resulting in copper oxide nanoparticles [62]. These CuSO₄ nanoparticles showed remarkable antibacterial activity against *V. parahemolyticus*, *V. harvey*, *Aeromonas hydrophila*, and *Serratia marcescens*.

Carrageenan is a water-soluble, high-molecular-weight, sulfated polysaccharide isolated from many species of red algae. Carrageenan has been widely used in the pharmaceutical, medical, and food industries due to its high viscosity, gelling capacity, and biocompatibility [63,64]. Vijayakumar et al. [65] synthesized Kappa-carrageenan wrapped zinc-oxide nanoparticles (KC-ZnONPs) with antibacterial and antibiofilm activity against Methicillin-resistant *S. aureus* (MRSA) (Figure 3). Based on hemocompatibility studies on human RBCs and eco-safety studies using *Artemia salina*, the synthesized KC-ZnONPs showed high biocompatibility and were non-toxic to the environment.

Fucoidan, a pure chemical derived from *Fucus vesiculosus*, was used to synthesize gold nanoparticles, which demonstrated antibacterial action against *P. aeruginosa* (MIC value of 512 µg/mL) [66]. In addition, the fucoidan-gold nanoparticles reduced the production of virulence factors, such as rhamnolipid, pyocyanin, and pyoverdine. Due to the presence of mannose, the capsular polymeric material isolated from marine *B. altitudinis* proved efficient as a stabilizer for CuO nanoparticle synthesis [67]. The MIC value of CuO nanoparticles containing mannose against *P. aeruginosa* was 1.0 µg/mL. Silver nanoparticles synthesized by the marine fungus *Aspergillus flavus* utilizing amylase showed antibacterial efficacy against Gram-positive and Gram-negative bacteria [68]. In particular, amylase-silver nanoparticles had the strongest antibacterial activity against *A. hydrophila* (MIC value of 1.6 µg/mL). Khan et al. [69] synthesized gold nanoparticles from chitosan oligosaccharide, a natural marine compound, to treat *P. aeruginosa* biofilm infections. Chitosan oligosaccharide-gold nanoparticles exhibited antibiofilm efficacy by lowering bacterial hemolysis and *P. aeruginosa* virulence factors. *P. aeruginosa* hemolysis and protease activity were reduced by a nanocomposite of chitosan and polypyrrole [70]. Moreover, the production of various virulence factors, such as rhamnolipid, pyoverdine, and pyocyanin was reduced by this nanocomposite.
5. Marine Bioinspired NPs Used for Fungal Infection

Fungal infection is a constant cause of death [71]. The number of fungal infection cases is increasing, and it has been claimed that over 150 million fungal infections occur yearly, with a 1.5 million death rate from fungal infection [72]. Several secondary metabolites with antifungal action are produced by marine microorganisms, mammals, and algae, similar to antibacterial activity [73]. Antifungal chemicals are produced by a variety of marine species, including bacterial chitinases, lipopeptides, and lactones [74]. Brown algae phlorotannins, on the other hand, have antifungal activity by altering the composition of ergosterol in the yeast cell membrane [75]. The marine depsipeptidepapuamide A has been shown to trigger fungus apoptosis by binding to phosphatidylserine in the cell membrane and entering the plasma membrane [76]. Plakortide F acid, a polyketide endoperoxide produced from marine sponges, also had antifungal activity through affecting \( \text{Ca}^{2+} \) homeostasis [77]. As a result, many researchers continue to look for antifungal activity in a variety of marine organisms for application to nanoparticles. Green synthesis of silver nanoparticles from \( U. \text{rigida} \) had antifungal action against the fungus \( \text{Trichophyton mantigrophytes} \) and \( T. \text{cutaneum} \), which are linked to skin infections [78].
Table 1. List of marine-bioinspired metallic nanoparticles treating infectious diseases.

| Name of Marine-Derived Compound/Product | Sources/Organism | Name of NPs | Size Range of MNPs | Shape/Morphology | Antimicrobial Types | Microbial Pathogens | References |
|-----------------------------------------|------------------|-------------|-------------------|------------------|--------------------|--------------------|------------|
| Extracts                                | Ulva rigida      | AgNPs       | 12 nm             | Spherical        | Antibacterial      | Bacillus cereus    | [78]       |
| Extracts                                | Cystoseira myrica|             |                   |                  |                    | Escherichia coli   |            |
| Extracts                                | Gracilaria foliifera|          |                   |                  |                    | Candida albicans   |            |
| Extracts                                |                  |             |                   |                  |                    | Staphylococcus aureus|            |
| Extracts                                |                  |             |                   |                  |                    | Cryptococcus neoformans|           |
| Extracts                                | U. lactuca       | AgNPs       | 20–50 nm          | -                | Antibacterial      | E. coli           | [79]       |
| Extracts                                |                  |             |                   |                  |                    | Enterobacter spp.  |            |
| Extracts                                |                  |             |                   |                  |                    | Klebsiella pneumonia|            |
| Extracts                                |                  |             |                   |                  |                    | Methicillin-resistant|            |
| Extracts                                |                  |             |                   |                  |                    | S. aureus (MRSA)   |            |
| Extracts                                |                  |             |                   |                  |                    | Pseudomonas aeruginosa|           |
| Extracts                                |                  |             |                   |                  |                    | S. aureus         |            |
| Extracts                                | Halimeda opuntia | SeNPs       | 30, 80 nm         | Spherical        | Antibacterial      | Vibrio harvey      | [80]       |
| Extracts                                | Kappaphycus alvarezii | |                   |                  |                    | V. parahaemolyticus|            |
| Extracts                                | Spirulina platensis| SNMP       | 200–450 nm        | Spherical        | Antibacterial      | V. parahaemolyticus| [81]       |
| Extracts                                | Chroococcus minutus| AgNPs      | -                 | -                | Antibacterial      | E. coli           | [56]       |
| Extracts                                |                  |             |                   |                  |                    | Streptococcus pyogenes|           |
| Extracts                                | U. lactuca       | SeNP        | 85 nm             | Spherical        | Antibacterial      | Lactobacillus      | [82]       |
| Extracts                                |                  |             |                   |                  |                    | C. albicans       |            |
|                                       |                  |             |                   |                  |                    | S. mutans         |            |
|                                       |                  |             |                   |                  |                    | S. aureus         |            |
| Name of Marine-Derived Compound/Product | Sources/Organism | Name of NPs | Size Range of MNPs | Shape/ Morphology | Antimicrobial Types | Microbial Pathogens | References |
|----------------------------------------|------------------|-------------|--------------------|------------------|-------------------|---------------------|-----------|
| Extracts Sargassum muticum             | AgNPs            | 20–54 nm    | Spherical          | Antibacterial     | E. coli           | [57]                |
| Extracts S. swartzii                   | AgNPs            | 20–40 nm    | Spherical          | Antibacterial     | E. coli           | [58]                |
| Extracts Gelidium corneum              | AgNPs            | 20–50 nm    | Spherical          | Antibacterial     | E. coli           | [83]                |
| Extracts Laminaria ochroleuca          | AgNPs            | 10–20 nm    | Spherical          | Antibacterial     | E. coli           | [84]                |
| Extracts Streptomyces sp. Al-Dhabi-87  | AgNPs            | 10–17 nm    | Spherical          | Antibacterial     | Enterococcus faecalis | [61]       |
| Extracts S. wightii                    | AgNPs            | 30–40, 55–70 nm | -                | Antibacterial     | M. luteus           | [59]                |
| Extracts Streptomyces sp. Rhodococcus rhodochrous | AgNPs | 5.52, 35 nm | Spherical | Antibacterial | B. subtilis | [85] |
|                                        |                  |             |                    |                  | E. coli           |                     |
|                                        |                  |             |                    |                  | P. aeruginosa     |                     |
|                                        |                  |             |                    |                  | S. aureus         |                     |
|                                        |                  |             |                    |                  | K. pneumoniae     |                     |
|                                        |                  |             |                    |                  | Micrococcus luteus|                     |
|                                        |                  |             |                    |                  |                   |                     |
Table 1. Cont.

| Name of Marine-Derived Compound/Product | Sources/Organism | Name of NPs | Size Range of MNPs | Shape/Morphology | Antimicrobial Types | Microbial Pathogens | References |
|----------------------------------------|------------------|-------------|-------------------|-----------------|--------------------|---------------------|------------|
| Extracts                               | Gelidiella acerosa | AgNPs       | -                 | -               | Antibacterial      | B. subtilis, P. aeruginosa, S. aureus | [60]       |
| Extracts                               | Acanthophora spicifera | AuNPs      | <20 nm            | Spherical       | Antibacterial      | V. harveyi, S. aureus | [86]       |
| Extracts                               | G. amansii        | AgNPs       | 27–54 nm          | Spherical       | Antibacterial      | Aeromonas hydrophila, V. parahaemolyticus, P. aeruginosa, E. coli, S. aureus, B. pumilus | [87]       |
| Extracts                               | S. wightii        | MgONPs      | 68.06 nm          | Flower          | Antibacterial      | S. pneumonia, MRSA, E. coli, P. aeruginosa, A. baumannii | [88]       |
| Extracts                               | Oscillatoria princeps | AgNPs     | 3.30–17.97 nm     | Spherical       | Antibacterial      | S. aureus, S. pyogenes, E. coli | [89]       |
### Table 1. Cont.

| Name of Marine-Derived Compound/Product | Sources/Organism                  | Name of NPs | Size Range of MNPs | Shape/ Morphology | Antimicrobial Types | Microbial Pathogens                          | References |
|----------------------------------------|-----------------------------------|-------------|--------------------|-------------------|---------------------|----------------------------------------------|------------|
| Extracts                               | *Nocardiopsis dassonvillei*-DS013 | AgNPs       | 30–80 nm           | Circular          | Antibacterial       | ● *Enterococcus* sp.                           | [90]       |
|                                        |                                   |             |                    |                   |                     | ● *Klebsiella* sp.                             |            |
|                                        |                                   |             |                    |                   |                     | ● *B. subtilis*                                |            |
|                                        |                                   |             |                    |                   |                     | ● *Streptococcus* sp.                          |            |
|                                        |                                   |             |                    |                   |                     | ● *Proteus* sp.                                |            |
|                                        |                                   |             |                    |                   |                     | ● *Pseudomonas* sp.                            |            |
|                                        |                                   |             |                    |                   |                     | ● *Shigella* sp.                               |            |
|                                        |                                   |             |                    |                   |                     | ● *E. coli*                                    |            |
| Extracts                               | *Streptomyces* sp. Al-Dhabi-87    | AgNPs       | 11–21 nm           | Cubic             | Antibacterial       | ● *B. subtilis*                                | [91]       |
|                                        |                                   |             |                    |                   |                     | ● *S. aureus*                                  |            |
|                                        |                                   |             |                    |                   |                     | ● *S. epidermidis*                             |            |
|                                        |                                   |             |                    |                   |                     | ● *P. aeruginosa*                              |            |
|                                        |                                   |             |                    |                   |                     | ● *E. coli*                                    |            |
|                                        |                                   |             |                    |                   |                     | ● *E. faecalis*                                |            |
|                                        |                                   |             |                    |                   |                     | ● *K. pneumoniae*                              |            |
| Extracts                               | *Penicillium polonicum*           | AgNPs       | 10 nm              | Spherical         | Antibacterial       | *A. baumanii*                                  | [44]       |
| Chitosan                               | Marine Seafood                    | AgNPs       | 5–20 nm            | Spherical         | Antibacterial       | ● *E. coli*                                    | [92]       |
|                                        |                                   |             |                    |                   |                     | ● *P. aeruginosa*                              |            |
| Chitosan                               | ● *Aspergillus* sp.               | Chitosan-AgNPs | 4.5 ± 20.0–50.2 ± 74.0 nm | Spherical | Antibacterial       | *S. aureus*                                   | [93]       |
|                                        | ● *Alternaria* sp.                | Chitosan-AuNPs | 3.47 ± 2.00–35.50 ± 2.00 nm |          |                     |                                               |            |
### Table 1. Cont.

| Name of Marine-Derived Compound/Product | Sources/Organism                  | Name of NPs | Size Range of MNPs | Shape/ Morphology | Antimicrobial Types          | Microbial Pathogens                                      | References |
|----------------------------------------|-----------------------------------|-------------|--------------------|------------------|-----------------------------|----------------------------------------------------------|------------|
| Extracts                               | **Chlorococcum humicola**         | AgNPs       | 10.69, 12.83 nm    | Spherical        | Antibacterial               | E. coli, S. Typhimurium [K. pneumoniae]                   | [94]       |
|                                        | **Chlorella vulgaris**            |             |                    |                  |                             |                                                          |            |
| Extracts                               | Cymodocea serrulata               | AgNPs       | 40.49–66.44 nm     | -                | Antibacterial               | V. parahaemolyticus [95]                                  |            |
|                                        | S. longifolium                    | CuONPs      | 40–60 nm           | -                | Antibacterial               | V. parahemolyticus, A. hydrophila, Serratia marcescens, V. harveyi [62] |
| Extracts                               | C. crinita                        | ZnONPs      | 23–200 nm          | Rectangular      | Antibacterial               | E. coli, B. cereus, S. Typhimurium, S. aureus, C. albicans, A. niger [96] |
| Extracts                               | Synechocystis sp.                 | AgNPs       | 10–35 nm           | Spherical        | Antibacterial               | MRSA [97]                                                |            |
| Extracts                               | O. limnetica                      | AgNPs       | 3.30–17.97 nm      | Quasi-spherical  | Antibacterial               | E. coli, B. cereus [98]                                  |            |
| Extracts                               | Red algae                         | Co₃O₄NPs    | 29.8 ± 8.6 nm      | Spherical        | Antibacterial               | P. aeruginosa, E. coli [99]                              |            |
| Extracts                               | U. lactuca                        | AgNPs       | 20–50 nm           | -                | Antiviral                   | Aedes aegypti, Culex pipiens [79]                        |            |
| Name of Marine-Derived Compound/Product | Sources/Organism | Name of NPs | Size Range of MNPs | Shape/ Morphology | Antimicrobial Types | Microbial Pathogens | References |
|----------------------------------------|------------------|-------------|--------------------|-------------------|---------------------|---------------------|------------|
| Extracts                               | Oscillatoria sp. | AgNPs       | 5.52–35.00 nm      | Spherical         | Antiviral           | Poliovirus          | [85]       |
| Extracts                               | Streptomyces sp. | AgNPs       | 50–65, 15–30, and 40–50 nm | Spherical         | Antiviral           | Newcastle disease virus | [101]       |
| Extracts                               | U. rigida        | AgNPs       | 12 nm              | Spherical         | Antifungal          | T. cutaneum         | [78]       |
| Extracts                               | S. griseus       | AgNPs       | 14.54 nm           | Spherical         | Antifungal          | C. albicans         | [102]       |
| Extracts                               | G. corneum       | AgNPs       | 20–50 nm           | Spherical         | Antifungal          | C. albicans         | [83]       |
| Extracts                               | P. fluorescens   | AgNPs       | -                  | -                 | Antifungal          | F. udum             | [103]       |
| Extracts                               | C. serrulate     | AgNPs       | -                  | -                 | Antifungal          | A. niger            | [103]       |
| Extracts                               | C. umhumicola    | AgNPs       | 10.69,12.83 nm     | Spherical         | Antifungal          | F. solani           | [94]       |
These silver nanoparticles produced an insoluble chemical that inactivated the fungal cell wall’s sulfhydryl group and disrupted the membrane, resulting in an antifungal effect. Silver nanoparticles synthesized from aqueous extracts of Cymodocea serrulata and Padina australis had antifungal action against plant fungi, including Pyripora oryzae, Alternaria sp., Helminthisporium oryzae, Rhizoctonia solani, and Xanthomonas oryzae [104]. These antifungals were discovered as a consequence of cell wall disruption, DNA damage, and an increase in ROS. Silver nanoparticles (AgNPs) synthesized from Gelidium corneum extract, which served as a reducing agent had excellent antifungal and antibiofilm properties against Candida albicans [83]. Biosynthetic silver nanoparticles, in particular, demonstrated antifungal effectiveness by generating cell membrane and cell wall destruction, as well as cytoplasmic damage (Figure 4).

Figure 4. Synthesis and characterization of AgNPs using extract of marine red algae Gelidium corneum with antimicrobial and antibiofilm inhibition characteristics towards Escherichia coli and Candida albicans. (A) UV-vis absorption spectra of AgNPs synthesized using extract in the presence of different silver salt concentrations and (B) Change in color of the reaction mixture indicates the formation of AgNPs. Reprinted with permission from reference [83]. Copyright, 2019 Elsevier Ltd.

6. Marine Bioinspired NPs for Treating Viral Infection

A viral particle is smaller than a live cell. Several viral infections have been documented to be caused by a pathogenic virus. Viruses cause a variety of diseases, leading to increased death rate. Viral infections include smallpox, polio, HIV, and hepatitis C [105]. Antiviral compounds produced by marine organisms include polyphenols, alkaloids, lipids, carbohydrates, steroids, terpenoids, exopolysaccharides, polyketides, zoanthoxanthins, and peptides [106]. Virus adsorption, penetration, capsid decoration, biosynthesis, virus assembly, and virus release are all inhibited or inactivated by marine polysaccharides [107]. One of the metabolites produced by marine organisms, phlorotannins, has been shown to interfere with viral attachment, penetration, and replication [15]. Silver nanoparticles
derived from the seaweed *U. lactuca* showed cytotoxic efficacy against the vector-borne pathogens *Aedes aegypti* and *Culex pipiens* [79]. Because of their small particle size, silver nanoparticles synthesized from *U. lactuca* demonstrated more effective action than conventional insecticides. Additionally, these silver nanoparticles bonded to the insect cuticle and entered within the cell, disrupting additional cell functions. Silver nanoparticles mediated by *Oscillatoria* sp. and gold nanoparticles mediated by *S. platensis* displayed antiviral efficacy against herpesvirus [100]. These nanoparticles induced glycoprotein aggregation and surface changes, both of which might inhibit viral binding and penetration. Silver nanoparticles derived from extracellular extracts of the marine actinomycetes *Rhodococcus rhodochrous* and *Streptomyces* sp. inhibited poliovirus in RD cells [85]. The interaction of viral proteins with silver nanoparticles caused poliovirus inhibition. Silver nanoparticles derived from *Dictyosphaerium* sp., a freshwater microalgae, had substantial antiviral activity against the Newcastle disease virus [101]. These silver nanoparticles were bound to the viral glycoprotein envelope, limiting virus penetration.

7. Marine Bioinspired NPs for Treating Non-Infectious Diseases

Table 2 shows studies that have used marine bioinspired nanoparticles to treat a wide range of non-infectious diseases. Inflammation is the body’s natural response to tissue injury, infection, and genetic alterations [108]. The immune system is activated within the body under inflammatory circumstances, resulting in the release of various inflammatory mediators, such as bradykinins and prostaglandins [109]. Thus, reducing prostaglandin levels can aid in the prevention of chronic disease by controlling inflammation [110]. To reduce inflammation and inflammatory mediators, steroids and nonsteroidal antiinflammatory medications constitute one of the treatment paths for inflammatory diseases [111]. These synthetic antiinflammatory drugs, on the other hand, can have substantial negative effects [112]. As a result, it is required to use marine-based organisms with high biological activity to generate nanoparticles with similar therapeutic benefits and no negative effects. Silver nanoparticles produced from macroalgae such as *Galaxaura elongate*, *Turbinaria ornate*, and *Enteromorpha flexuosa* have shown considerable antiinflammatory action via membrane stabilization [113]. Silver nanoparticles, in particular, reduced prostaglandin production by inhibiting protein denaturation, cyclooxygenase, and 5-lipoxygenase. At 500 µg/mL, ZnO nanoparticles wrapped in Kappa-carrageenan demonstrated 82% antiinflammatory efficacy (Figure 3) [65]. Because of their high surface area to volume ratio, these nanoparticles were more effective than bulk materials in inhibiting cytokines and inflammatory coenzymes. Cancer is caused by the uncontrollable growth of cells and tissues [114]. Cancer treatment options include surgery, radiation, and potentially toxic medication therapy [115]. As a result, several investigations are being done to discover anticancer drugs that kill cancer cells without hurting humans [116]. Nanoparticles loaded with various physiologically active chemicals are one of the most effective drug delivery techniques for cancer therapy [117]. Marine-derived natural products, in particular, are potential molecules for the development of anticancer drugs because they may influence multiple pathways, such as immunity, cancer cell death, and tumor growth [118]. Silver nanoparticles derived from *Caulerpa taxifolia* showed antitumor efficacy against A549 lung cancer cells [119]. Necrosis and condensation of A549 cells were shown to be mediated by silver nanoparticles derived from marine algae, suggesting that nanomaterials are relevant for cancer cell research. Furthermore, gold nanoparticles inhibited phosphorylation of AKT and ERK, which are essential for cell growth in HeLa cancer cells [47]. Interestingly, these gold nanoparticles derived from jellyfish extract exhibited a significant lethal effect on HeLa cancer cells. Cu2O nanoparticles derived from *Rhodotorula mucilaginosa* showed anticancer activity against SKOV-3, MCF-7, HepG2, A549, SW620, and HT-29 [117]. In particular, reactive oxygen species production and oxidative stress enhanced the anticancer mechanism of Cu2O nanoparticles. Similarly, Shunmugam et al. [120] synthesized gold nanoparticles from the marine bacterium *V. alginolyticus*, which had antioxidant and anticancer activity (Figure 5). The anticancer activity was attributed to the treated cells’ nuclear condensation.
Table 2. List of marine-bioinspired metallic nanoparticles for treating non-infectious diseases.

| Name of Marine-Derived Compound/Product | Organisms/Sources                  | Name of NPs | Size Range of MNPs | Shape/Morphology | Types of Non-Infectious Disease Treatment | Effects/Activities | References |
|----------------------------------------|-----------------------------------|-------------|--------------------|------------------|------------------------------------------|-------------------|------------|
| Extracts                               | • *Ulva rigida* • *Cystoseira myrica* • *Gracilaria folifera* | AgNPs       | 12 nm              | Spherical         | Anticancer                               | Human breast adenocarcinoma cell line | [78]       |
| Extracts                               | • *Streptomyces sp.* • *Rhodococcus rhodochrous* | AgNPs       | 5.52, 35 nm        | Spherical         | Anticancer Anti-leishmanial               | HepG2 cell line, Leishmania tropica | [85]       |
| Extracts                               | *Acanthophora spicifera*          | AuNPs       | <20 nm             | Spherical         | Anticancer                               | Human colon adenocarcinoma (HT-29) cells | [86]       |
| Extracts                               | *Sargassum wightii*               | MgONPs      | 68.06 nm           | Flower            | Anticancer                               | A549              |            |
| Extracts                               | *Rhodotorula mucilaginosa*        | Cu$_2$ONPs  | 51.6–111.4 nm      | Spherical         | Anticancer                               |                  | [117]      |
| Extracts                               | *Pterocladia capillacea*          | CuONPs      | 62 nm              | Spherical         | Anticancer                               | Breast cancer, ovarian cancer, and hepatocellular carcinoma cell lines | [121]      |
| Extracts                               | *Laminaria digitata*              | ZnONPs      | 100–350 nm         | Spindle           | Anticancer                               | Fibroblasts cells and human colon cancer cells | [122]      |
| Extracts                               | *Hamigera pallidass*              | AgNPs       | 5.85 ± 0.84, 3.69–16.11 nm | Spherical | Anticancer Antioxidant                   | Human breast cancer, DPPH (2, 2-diphenyl1-picrylhydrazyl) | [123]      |
| Name of Marine-Derived Compound/Product | Organisms/Sources | Name of NPs | Size Range of MNPs | Shape/Morphology | Types of Non-Infectious Disease Treatment | Effects/Activities | References |
|----------------------------------------|-------------------|-------------|--------------------|------------------|----------------------------------------|-------------------|-----------|
| Extracts                               | • Galaxaura elongate  
• Turbinaria ornata  
• Enteromorpha flexuosa | AgNPs | 30–90, 20–60, 30–90 nm | Spherical | • Anticancer  
• Antioxidant  
• Antidiabetic  
• Antiinflammatory | • HepG2  
• DPPH, ABTS scavenger  
• α-Amylase inhibition  
• Protease inhibition and albumin denaturation inhibition | [113] |
| Extracts                               | U. lactuca        | AgNPs | 8–14 nm            | Spherical | Anticancer | Human colon cancer | [124] |
| Extracts                               | Alternaria chlamydospora | AuNPs | -                 | Spherical | • Anticancer  
• Antioxidant | A549 cell lines  
• DPPH | [125] |
| Extracts                               | • Chondrus crispus  
• Gelidium corneum  
• Porphyra linearis | AuNPs | 16.9 ± 2.5, 15.0 ± 3.0, 44.2 ± 6.1 nm | Spherical | • Antitumoral  
• Antioxidant | Monocytic cell line  
• Human promyelocytic cells | [126] |
| Extracts                               | C. crinita        | ZnONPs | 23–200 nm         | Rectangular | Antioxidant | DPPH | [96] |
| Extracts                               | Synechocystis sp. | AgNPs | 10–35 nm          | Spherical | Wound-healing | Diabetic wounded animals | [97] |
| Carrageenan & Carrageenan oligosaccharide | Marine red algae | AuNPs | 141 ± 6 nm        | Spherical | Anticancer | HCT-116 and HepG2 cells | [127] |
| Extracts                               | Paracoccus haemodiscis | AuNPs | 20.93 ± 3.46 nm  | Spherical | • Anticancer  
• Antioxidant | A549  
• AGS cancer cells  
• DPPH | [128] |
| Extracts                               | Caulerpa taxifolia | AgNPs | -                 | - | Anticancer | A549 lung cancer cells | [119] |
| Extracts                               | Nemopilema nomurai | AuNPs | 35.2 ± 8.7 nm    | Spherical | Anticancer | HeLa cancer cells | [47] |
Table 2. Cont.

| Name of Marine-Derived Compound/Product | Organisms/Sources | Name of NPs | Size Range of MNPs | Shape/Morphology | Types of Non-Infectious Disease Treatment | Effects/Activities | References |
|----------------------------------------|-------------------|-------------|-------------------|------------------|-------------------------------------------|------------------|-----------|
| Extracts                               | Oscillatoria limnetica | AgNPs      | 3.30–17.97 nm     | Quasi-spherical  | Anticancer                                | • Human colon cancer cell line 
• Human breast cell line | [98]       |
| Extracts                               | Red algae         | Co₃O₄NPs   | 29.8 ± 8.6 nm     | Spherical        | Anticancer                                | HepG2 cancer cells | [99]       |
| Extracts                               | Vibrio alginolyticus | AuNPs      | 50–100 nm         | Monodispersed, irregular shape | Anticancer | HCA-7 cells | [120]     |
Silver nanoparticles derived from shrimp shell chitin acted as a reducing agent and had anticancer action against human hepatocarcinoma [129]. In HepG2 cells, chitin-silver nanoparticles increased the expression of apoptosis-related proteins Bax, PARP, cytochrome-c, caspase-3, and caspase-9, while decreasing the expression of anti-apoptosis proteins Bcl-2 and Bcl-xl. Phloroglucinol-encapsulated starch biopolymer exhibited dose-dependent anticancer activities against the HepG2 liver cancer cell line [130]. These findings were ascribed to the biopolymer’s hydrophobicity, which increased adhesion and adsorption capability to the cancer cell surface.

Cells produce potentially harmful ROS as a result of oxygen metabolism, which involves enzymatic and non-enzymatic reactions [131]. High levels of ROS caused by oxidative stress induce a variety of diseases in the body, including diabetes, hypertension, and Alzheimer’s [132]. Antioxidants, on the other hand, have a role in delaying, regulating, and avoiding the oxidative process that leads to the beginning and progression of the disease [133]. Through SOD enzymes, which catalyze the recombination of oxygen radicals, these antioxidants counteract the consequences of oxidative stress [134].

Figure 5. Anticancer and antioxidant properties of gold nanoparticles synthesized using marine microbe *Vibrio alginolyticus*. Reprinted with permission from reference [120]. Copyright 2020, Elsevier B.V.
Silver nanoparticles derived from shrimp shell chitin acted as a reducing agent and had anticancer action against human hepatocarcinoma [129]. In HepG2 cells, chitin-silver nanoparticles increased the expression of apoptosis-related proteins Bax, PARP, cytochrome-c, caspase-3, and caspase-9, while decreasing the expression of antiapoptosis proteins Bcl-2 and Bcl-xl. Phloroglucinol-encapsulated starch biopolymer exhibited dose-dependent anticancer activities against the HepG2 liver cancer cell line [130]. These findings were ascribed to the biopolymer’s hydrophobicity, which increased adhesion and adsorption capability to the cancer cell surface.

Cells produce potentially harmful ROS as a result of oxygen metabolism, which involves enzymatic and non-enzymatic reactions [131]. High levels of ROS caused by oxidative stress induce a variety of diseases in the body, including diabetes, hypertension, and Alzheimer’s [132]. Antioxidants, on the other hand, have a role in delaying, regulating, and avoiding the oxidative process that leads to the beginning and progression of the disease [133]. Through SOD enzymes, which catalyze the recombination of oxygen radicals, these antioxidants counteract the consequences of oxidative stress [134]. Currently, research is being performed to investigate natural substances capable of controlling oxidative stress, which leads to the investigation of nanoparticles with antioxidant activities. Many species with antioxidant activity in marine organisms, in particular, have been found and have piqued the interest of researchers due to their potential biological activity [135]. The antioxidant activity of gold nanoparticles produced by the marine fungus A. chlamydospora (inhibition of DPPH radicals) was dose-dependent [125]. Furthermore, in a concentration-dependent way, gold nanoparticles mediated by the marine bacteria Paracoccus haenaundaensis cell-free supernatant demonstrated strong reducing power via DPPH scavenging activity [128]. Selenium nanoparticles produced from Spirulina phycocyanin protected INS-1E rat insulinoma cells against palmitic acid-induced cell death [136]. Phycocyanin and selenium shielded cells from oxidative damage and signaling pathways downstream. These findings indicate that marine-derived nanoparticles can be employed as effective natural antioxidants.

Figure 6 depicts the biological activity of nanoparticles synthesized using phloroglucinol. Silver nanoparticles synthesized using phloroglucinol showed anticancer efficacy against the MCF-7 breast cancer cell line [137]. Silver ions from phloroglucinol silver nanoparticles entered cancer cells and interacted with intracellular macromolecules, such as organelles, proteins, and DNA, to trigger apoptosis. Another study found that phloroglucinol-gold nanoparticles triggered death in HeLa cancer cells via enhancing mitochondrial membrane permeability [138]. Phloroglucinol-encapsulated chitosan nanoparticles showed antibiofilm action against single-species biofilms, such as K. pneumoniae, S. aureus, S. mutans, and C. albicans, and mixed-species biofilms, such as C. albicans-S. aureus/K. pneumoniae/S. mutans [139]. Gold and zinc oxide nanoparticles produced with phloroglucinol showed significant antibacterial action against P. aeruginosa [140]. Moreover, these nanoparticles inhibited P. aeruginosa twitching, swimming, and swarming motility, all of which have virulence features. Similarly, several marine-derived pure compounds are employed in synthesizing nanoparticles and encapsulating drugs for application in the field of medicine (Table 3).
**Figure 6.** Application of phloroglucinol in the form of nanoparticles for treating infectious and non-infectious diseases. (A) The cytotoxicity action of phloroglucinol-engineered AgNPs towards MCF-7 breast cancer cell lines. (a) SEM image of AgNPs and (b) TEM image of AgNPs. Reproduced with permission from reference [137]. (B) Synthesis of the phloroglucinol-conjugated gold nanoparticles, which exhibit therapeutic potential towards cancer cells. The action mechanism involved apoptosis of cancer cells by promoting mitochondrial transmembrane permeation, as evident by fluorescence staining and gene expression studies. Reprinted with permission from reference [138], (C) Encapsulation of phloroglucinol into the chitosan nanoparticles. The PG-CSNPs exhibit antibiofilm properties towards single- and mixed-species biofilms of *C. albicans-S. aureus-S. mutans-K. pneumoniae*. Reprinted with permission from reference [139], and (D) Synthesis of metal (AuNPs) and metal oxide (ZnONPs) nanoparticles using phloroglucinol. The synthesized PG-AuNPs and PG-ZnONPs showed antibiofilm and antivirulence properties towards *P. aeruginosa*. Reproduced with permission from reference [140]. Copyright 2021 by the authors and licensee MDPI, Basel, Switzerland.
Table 3. Application of marine-derived compounds in the synthesis of nanoparticles and encapsulation of drugs for application in the field of medicine.

| Classification of Sources | Natural Pure Compounds | Types of Nanomaterial | Size                 | Morphology          | Biological Activity                                                                 | Action Mechanism                                                                                      | References |
|---------------------------|------------------------|-----------------------|----------------------|---------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|------------|
| Algae                     | Fucoidan               | AuNPs                 | ~53 nm               | Spherical           | Antibacterial activity against *Pseudomonas aeruginosa*                              | • Reduced the generation of numerous important virulence factors                                      | [66]       |
|                           |                        |                       |                      |                     |                                                                                     | • Impaired bacterial motility, including twitching, swimming, and swarming                           |            |
| Algae                     | Phloroglucinol         | AuNPs and ZnONPs      | 41.6 ± 3.9, 52.7 ± 3.8 nm | Spherical and hexagonal | Antibacterial activity against *P. aeruginosa*                                      | • *P. aeruginosa* virulence factors, such as rhamnolipid, pyocyanin, pyoverdine, protease, and hemolytic capabilities, were reduced. | [140]     |
|                           |                        |                       |                      |                     |                                                                                     | • Impaired bacterial motility, including twitching, swimming, and swarming                           |            |
| Algae                     | Phycocyanin            | SeNPs                 | 165, 235, 371, 815 nm | Spherical           | Antioxidant                                                                        | Protected INS-1E cells against palmitic acid-induced cell death by reducing oxidative stress and signaling pathways downstream | [136]     |
| Algae                     | Fucoxanthin            | AgNPs                 | 20–25 nm             | Spherical           | Antibacterial activity against *Escherichia coli*, *Bacillus stearothermophilus*, and *Streptococcus mutans* | -                                                           | [141]     |
| Algae                     | Phloroglucinol         | Starch biopolymer     | 1–100 nm             | Spherical           | Anticancer                                                                          | Adhesion and adsorption on the surfaces of cancer cells are enhanced                                 | [130]     |
| Classification of Sources | Natural Pure Compounds | Types of Nanomaterial | Size | Morphology | Biological Activity | Action Mechanism | References |
|---------------------------|------------------------|-----------------------|------|------------|--------------------|-----------------|------------|
| Algae                     | Phloroglucinol         | CSNPs                 | 414.0 ± 48.5 nm | Spherical | Antibiofilm activity against *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Candida albicans*, *S. mutans*, and mixed-species such as *C. albicans*-*S. aureus*/*K. pneumoniae*/*S. mutans* | The positive charge of CSNPs allows for easy biofilm penetration and binding | [139] |
| Algae                     | Usnic acid             | Nanofibrous poly(ε-caprolactone)/decellularized extracellular matrix scaffolds | 3.89 ± 2.52, 4.95 ± 2.19, 5.00 ± 2.05 µm | Fusion of the fiber junctions | • Antibacterial activity against *Cutibacterium acnes*, *S. mutans*, *S. aureus*, *S. epidermidis*, and *C. albicans*  
• Antibiofilm activity against *K. pneumoniae* and *P. aeruginosa*  
• Wound healing capability | • Increased swelling, surface erosion, and degradation due to high release qualities  
• Improved cellular activities, such as cell adhesion, proliferation, differentiation, and migration | [142] |
| Algae                     | Carrageenan            | ZnONPs                | 97.03 ± 9.05 nm | Hexagonal wurtzite phase | • Antibacterial activity against MRSA  
• Antiinflammatory activity | • Penetrated quickly through the bacterial cell membrane and had a greater bactericidal impact  
• Inflammation enhancers such as cytokines and inflammation-assist enzymes are blocked | [65] |
| Bacteria                  | Mannose                | CuONPs                | 108 nm | Spherical | Antibacterial activity against *P. aeruginosa* | Entered the cell membrane, causing lysis and cell rupture | [67] |
| Fungi                     | • Asperpyrone B        | AgNPs                 | 8–30 nm | Spherical | Acetylcholine esterase inhibitory activity | Enzyme structural alterations | [143] |
| Fungi                     | • Asperpyrone C        |                       |       |            |                     |                 |            |
| Fungi                     | α-amylase              | AgNPs                 | 22.88–26.35 nm | Spherical | Antibacterial activity against *Aeromonas hydrophila*, *P. aeruginosa*, *Vibrio anguillarum*, *S. faecium*, *S. agalactiae*, and *Listeria spp.* | Damage to cell membranes, oxidative stress, and protein and DNA damage | [68] |
Table 3. Cont.

| Classification of Sources | Natural Pure Compounds | Types of Nanomaterial | Size         | Morphology     | Biological Activity                                                                 | Action Mechanism                                                                                     | References |
|---------------------------|------------------------|-----------------------|--------------|----------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------|
| Animal                    | Chitin                 | AgNPs                 | 17–49 nm     | Spherical      | Anticancer activity in human hepatocellular carcinoma HepG2 cells                     | • Increased levels of apoptosis-related proteins, such as PARP, cytochrome-c, Bax, caspase-3, and caspase-9<br>• Reduced expression of the antiapoptotic proteins Bcl-xL and Bcl-2 in HepG2 cells | [129]      |
| Animal                    | Astaxanthin            | AuNPs                 | 58.2 ± 4.6 nm| Polygonal and spherical | Antioxidant                                                                             | Reduced ROS and increased antioxidant enzyme activity in rice plants treated to Cd to alleviate oxidative stress | [144]      |
| Animal                    | Chitosan oligosaccharide| AuNPs                | 56.01 ± 3.48 nm | Spherical      | Antibacterial activity against *P. aeruginosa*                                         | • Inhibited bacterial hemolysis<br>• Reduced *P. aeruginosa* virulence factor synthesis<br>• Reduced bacterial swimming and twitching motilities | [69]       |
| Animal                    | Thiol chitosan         | AuNSs                 | 185 ± 19 nm  | Spherical      | Antibacterial activity against *E. coli, P. aeruginosa, and S. aureus*                 | -                                                                                                    | [145]      |
| Animal                    | Chitosan               | Polypyrrole nanocomposites | 55.77 ± 3.48 nm | Spherical      | Antibiofilm activity against *P. aeruginosa*                                         | • *P. aeruginosa* hemolytic and protease activities were inhibited<br>• Reduced the production of many virulence factors, including pyocyanin, pyoverdine, and rhamnolipid | [70]       |
8. Conclusions and Future Perspectives

In conclusion, because of their potential biological activity, marine-derived products have been widely used in the pharmaceutical industry. With an increased understanding of their biological functions, various marine-derived compounds have been used in the synthesis of nanoparticles. These products comprised polymers, organic compounds, and extract, which act as a powerful reducing agent in synthesizing metal and metal-oxide nanoparticles. Furthermore, certain polymeric material is used to effectively deliver the drug in the treatment of infectious and non-infectious diseases. The review detailed the list of the marine organism from which the extract was extracted and which was used to synthesize several forms of nanoparticles. Furthermore, these nanoparticles have been shown to have antimicrobial properties against bacterial, fungal, and viral pathogens. Antimicrobial mechanisms include the breakdown of cell membranes, as well as damage to cell walls and DNA. These marine-inspired nanoparticles have also shown promise in the treatment of non-infectious diseases, such as diabetes, cancer, wounds, inflammatory reactions, and leishmanial infections. Though significant progress has been made in the production of nanoparticles utilizing extracts from marine sources, relatively little information is known on the synthesis of nanoparticles using pure active compounds. This is because of the fact that there are several variations in extract preparation due to a number of environmental factors. As a result, future research should prioritize the use of pure active compounds for nanoparticle synthesis. Most antimicrobial research involving these nanoparticles has been conducted at the phenotypic level; however, investigations at the gene level are highly needed to explain the molecular mechanism.

Author Contributions: G.-J.J.: Literature Search, Writing—original draft and Editing, S.K.; Literature Search, Writing—original draft, and Editing, N.T.: Literature Search, Writing—original draft and Editing, F.K.: Conceptualization, Literature Search, Writing—original draft, and Writing—review and Editing, Y.-M.K.: Supervision, Funding, Writing—review and Editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education (2021R1A6A1A03039211 and 2022R1A2B601001998).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. World Health Organization. Global Health Estimates 2015: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2015; WHO: Geneva, Switzerland, 2016.
2. Hoffmann, A.R.; Proctor, L.; Surette, M.; Suchodolski, J. The microbiome: The trillions of microorganisms that maintain health and cause disease in humans and companion animals. Vet. Pathol. 2016, 53, 10–21. [CrossRef]
3. Deen, J.; Mengel, M.; Clemens, J. Epidemiology of Cholera. Vaccine 2020, 38 (Suppl. S1), A31–A40. [CrossRef] [PubMed]
4. Pappas, P.G.; Lionakis, M.S.; Arendrup, M.C.; Ostrosky-Zeichner, L.; Kullberg, B.J. Invasive candidiasis. Nat. Rev. Dis. Primers 2018, 4, 18026. [CrossRef] [PubMed]
5. World Health Organization. Responding to Community Spread of COVID-19. Reference WHO/COVID-19/Community_Transmission/2020.1; WHO: Geneva, Switzerland, 2020.
6. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2021; WHO: Geneva, Switzerland, 2021.
7. Chakraborty, S.; Rahman, T. The difficulties in cancer treatment. Ecamcancermedicalscience 2012, 6, ed16. [CrossRef] [PubMed]
8. Hurt, R.T.; Kulisek, C.; Buchanan, L.A.; McClave, S.A. The obesity epidemic: Challenges, health initiatives, and implications for gastroenterologists. Gastroenterol. Hepatol. 2010, 6, 780.
10. Hoffman, P.S. Antibacterial discovery: 21st century challenges. *Antibiotics* **2020**, *9*, 213. [CrossRef]

11. Sedeek, A.M.; Ismail, M.M.; Elsayed, T.R.; Ramadan, M.A. Recent methods for discovering novel bioactive metabolites, specifically antimicrobial agents, from marine-associated microorganisms. *Lett. Appl. Microbiol.* **2022**, [CrossRef]

12. Patil, M.P.; Kim, G.-D. Marine microorganisms for synthesis of metallic nanoparticles and their biomedical applications. *Colloids Surf. B Biointerfaces* **2018**, *172*, 487–495. [CrossRef]

13. Montuori, E.; de Pascale, D.; Lauritano, C. Recent Discoveries on Marine Organism Immunomodulatory Activities. *Mar. Drugs* **2022**, *20*, 422. [CrossRef]

14. Yosri, N.; Khalifa, S.A.; Guo, Z.; Xu, B.; Zou, X.; El-Seedi, H.R. Marine organisms: Pioneer natural sources of polysaccharides/proteins for green synthesis of nanoparticles and their potential applications. *Int. J. Biol. Macromol.* **2021**, *193*, 1767–1798. [CrossRef] [PubMed]

15. Khan, F.; Jeong, G.-J.; Khan, M.S.A.; Tabassum, N.; Kim, Y.-M. Seaweed-Derived Phlorotannins: A Review of Multiple Biological Roles and Action Mechanisms. *Mar. Drugs* **2020**, *20*, 384. [CrossRef] [PubMed]

16. Fang, Y.; Li, H.; Ji, B.; Cheng, K.; Wu, B.; Li, Z.; Zheng, C.; Hua, H.; Li, D. Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification. *Eur. J. Med. Chem.* **2021**, *210*, 113092. [CrossRef]

17. Bayda, S.; Adeel, M.; Tuccinardi, T.; Cordani, M.; Rizzolio, F. The history of nanoscience and nanotechnology: From chemical–physical applications to nanomedicine. *Molecules* **2019**, *25*, 112. [CrossRef] [PubMed]

18. Khalil, M.A.; El-Shanshoury, A.E.-R.R.; Alghamdi, M.A.; Alsalmi, F.A.; Mohamed, S.F.; Sun, J.; Ali, S.S. Biosynthesis of silver nanoparticles by Marine actinobacterium *Nocardiopsis dassonvillei* and exploring their therapeutic potentials. *Front. Microbiol.* **2021**, *12*, 705673. [CrossRef]

19. Vala, A.; Shah, S. Rapid synthesis of silver nanoparticles by a marine-derived fungus *Aspergillus niger* and their antimicrobial potentials. *Int. J. Nanosci. Nanotechnol.* **2012**, *8*, 197–206. [CrossRef]

20. Hammami, I.; Alabdallah, N.M. Gold nanoparticles: Synthesis properties and applications. *J. King Saud Univ. Sci.* **2021**, *33*, 101560. [CrossRef] [PubMed]

21. Spirescu, V.A.; Chircov, C.; Grumezeascu, A.M.; Vasile, B.S.; Andronescu, E. Inorganic nanoparticles and composite films for antimicrobial therapies. *Int. J. Mol. Sci.* **2021**, *22*, 4595. [CrossRef]

22. Balakumaran, M.; Ramachandran, R.; Balashanmugam, P.; Mukeskumar, D.; Kaliichelvan, P. Mycosynthesis of silver and gold nanoparticles: Optimization, characterization and antimicrobial activity against human pathogens. *Microbiol. Res.* **2016**, *182*, 8–20. [CrossRef] [PubMed]

23. Gnanajobitha, G.; Paulkumar, K.; Vanaja, M.; Rajeshkumar, S.; Malarkodi, C.; Annadurai, G.; Kannan, C. Fruit-mediated synthesis of silver nanoparticles using *Vitis vinifera* and evaluation of their antimicrobial efficacy. *J. Nanostructure Chem.* **2013**, *3*, 67. [CrossRef]

24. Song, X.; Shi, X.; Yang, M. Dual application of Shewanella oneidensis MR-1 in green biosynthesis of Pd nanoparticles supported on TiO$_2$ nanotubes and assisted photocatalytic degradation of methylene blue. *IET Nanobiotechnol.* **2018**, *12*, 441–445. [CrossRef] [PubMed]

25. Kumar, D.A.; Palanichamy, V.; Roopan, S.M. Green synthesis of silver nanoparticles using Alternanthera dentata leaf extract at room temperature and their antimicrobial activity. *Spectrochim. Acta Part A Mol. Biomol. Spectrosc.* **2014**, *127*, 168–171. [CrossRef]

26. Jin, R. The impacts of nanotechnology on catalysis by precious metal nanoparticles. *Nanotechnol. Rev.* **2012**, *1*, 31–56. [CrossRef]

27. Nagarajan, R. *Nanoparticles: Building Blocks for Nanotechnology*; ACS Publications: Washington, DC, USA, 2008.

28. Dash, D.K.; Panik, R.K.; Sahu, A.K.; Tripathi, V. Role of nanobiotechnology in drug discovery, development and molecular diagnostic. In *Applications of Nanobiotechnology*; IntechOpen: London, UK, 2020.

29. Mahmood Ansari, S.; Saquib, Q.; De Matteis, V.; Awad Alwathani, H.; Al Alharbi, S.; Ali Al-Khedhairy, A. Marine Macroligase Display Bioreduetant Efficacy for Fabricating Metallic Nanoparticles: Intra/Extracellular Mechanism and Potential Biomedical Applications. *Bioinorg. Chem. Appl.* **2021**, *2021*, 5985377. [CrossRef] [PubMed]

30. Ponyunuchamy, K.; Jacob, J.A. Metal nanoparticles from marine seaweeds—A review. *Nanotechnol. Rev.* **2016**, *5*, 589–600. [CrossRef]

31. Daraio, C.; Jin, S. Synthesis and patterning methods for nanostructures useful for biological applications. In *Nanotechnology for Biology and Medicine*; Springer: Berlin/Heidelberg, Germany, 2012; pp. 27–44.

32. Sardar, M.; Mazumder, J.A. Biomolecules assisted synthesis of metal nanoparticles. In *Environmental Nanotechnology*; Springer: Berlin/Heidelberg, Germany, 2019; pp. 1–23.

33. Asmathunisha, N.; Kathiresan, K. A review on biosynthesis of nanoparticles by marine organisms. *Colloids Surf. B Biointerfaces* **2013**, *103*, 283–287. [CrossRef]

34. Ehrlich, H. *Marine Biological Materials of Invertebrate Origin*; Springer: Berlin/Heidelberg, Germany, 2019.

35. Mora, C.; Tittensor, D.P.; Adl, S.; Simpson, A.G.; Worm, B. How many species are there on Earth and in the ocean? *PLoS Biol.* **2011**, *9*, e1001127. [CrossRef] [PubMed]

36. Russo, P.; Kisialiou, A.; Lamouna, P.; Moroni, R.; Prinzi, G.; Fini, M. New drugs from marine organisms in Alzheimer’s disease. *Mar. Drugs* **2015**, *14*, 5. [CrossRef]
37. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* 2016, 33, 382–431. [CrossRef]
38. Cardoso, J.; Nakayama, D.G.; Sousa, E.; Pinto, E. Marine-derived compounds and prospects for their antifungal application. *Molecules* 2020, 25, 5856. [CrossRef]
39. Simat, V.; Elabed, N.; Kulawik, P.; Ceylan, Z.; Jamroz, E.; Vazgan, H.; Cagali, M.; Regenstein, J.M.; Ozogul, F. Recent advances in marine-based nutraceuticals and their health benefits. *Mar. Drugs* 2020, 18, 627. [CrossRef] [PubMed]
40. Suárez Quintana, W.H.; García-Rico, R.O.; García-Martínez, J.B.; Urbina-Suárez, N.A.; López-Barrera, G.L.; Barajas-Solano, A.F.; Zuurro, A. Enhancement of Metalloenzyme Production in High-Altitude Microalgal Strains by Optimized C/N/P Ratio. *Appl. Sci.* 2022, 12, 6779. [CrossRef]
41. Priyadarshini, E.; Priyadarshini, S.S.; Pradhan, N. Heavy metal resistance in algae and its application for metal nanoparticle synthesis. *Appl. Microbiol. Biotechnol.* 2019, 103, 3297–3316. [CrossRef] [PubMed]
42. Oukarroum, A.; Bras, S.; Perneault, F.; Popovic, R. Inhibitory effects of silver nanoparticles in two green algae, Chlorella vulgaris and Dunaliella tertiolecta. *Ecotoxicol. Environ. Saf.* 2012, 78, 80–85. [CrossRef] [PubMed]
43. Venkatesan, J.; Kim, S.-K.; Shim, M.S. Antimicrobial, antioxidant, and anticancer activities of biosynthesized silver nanoparticles using marine alga Ecklonia cava. *Nanomaterials* 2016, 6, 235. [CrossRef]
44. Neethu, S.; Midhun, S.; Radhakrishnan, E.; Jyothis, M. Green synthesized silver nanoparticles by marine endophytic fungus Penicillium polonicum and its antibacterial efficacy against biofilm forming, multidrug-resistant *Acinetobacter baumannii*. *Microb. Pathog.* 2018, 116, 263–272. [CrossRef]
45. Wang, L.; Liu, C.-C.; Wang, Y.-Y.; Xu, H.; Su, H.; Cheng, X. Antibacterial activities of the novel silver nanoparticles biosynthesized using *Corydalis miltiorrhiza* extract. *Curr. Appl. Phys.* 2016, 16, 969–973. [CrossRef]
46. Srivastava, S.K.; Yamada, R.; Ogino, C.; Kondo, A. Biogenic synthesis and characterization of gold nanoparticles by *Streptomyces* K12 and its heterogeneous catalysis in degradation of 4-nitrophenol. *Nanoscale Res. Lett.* 2013, 8, 70. [CrossRef]
47. Ahn, E.-Y.; Hwang, S.J.; Choi, M.-J.; Cho, S.; Lee, H.-J.; Park, Y. Upcycling of jellyfish (*Nemopilema nomurai*) sea wastes as highly valuable reducing agents for green synthesis of gold nanoparticles and their antitumor and anti-inflammatory activity. *Artif. Cells Nanomed. Biotechnol.* 2018, 46 (Suppl. 52), 1127–1136. [CrossRef]
48. Yan, N.; Chen, X. Sustainability: Don’t waste seafood waste. *Nature* 2015, 524, 155–157. [CrossRef]
49. Doron, S.; Asnis, J.; Häfeli, U.O.; Bach, H. Metal nanoparticles: Understanding the mechanisms behind antibacterial activity. *J. Nanobiotechnol.* 2017, 15, 65. [CrossRef] [PubMed]
50. Shannon, E.; Abu-Ghannam, N. Antibacterial derivatives of marine algae: An overview of pharmacological mechanisms and applications. *Mar. Drugs* 2016, 14, 81. [CrossRef] [PubMed]
51. Nalini, S.; Richard, D.S.; Riyaz, S.M.; Kavitha, G.; Inbakandan, D. Antibacterial macro molecules from marine organisms. *Int. J. Biol. Macromol.* 2018, 115, 696–710. [CrossRef]
52. Gram, L.; Melchiorsen, J.; Bruhn, J.B. Antibacterial activity of marine culturable bacteria collected from a global sampling of ocean surface waters and surface swabs of marine organisms. *Mar. Biotechnol.* 2010, 12, 439–451. [CrossRef]
53. Qi, S.-H.; Xu, Y.; Gao, J.; Qian, P.-Y.; Zhang, S. Antibacterial and antilarval compounds from marine bacterium *Pseudomonas rhizophaeae*. *Ann. Microbiol.* 2009, 59, 229–233. [CrossRef] [PubMed]
54. Cox, S.; Abu-Ghannam, N.; Gupta, S. An assessment of the antibiotic and antimicrobial activity of six species of edible Irish seaweeds. *Int. Food Res. J.* 2015, 22, 17. [CrossRef]
55. Cahoon, D.R.; Hines, H.E.; Sackett, D.L.; Aller, R.C.; Van Dolah, F.; Bishop, B.D. Nutrient limitation of primary production in the open ocean. *Limnol. Oceanogr.* 1997, 42, 986–998. [CrossRef]
56. Savenije, H.H.H. Marine-based nutraceuticals and their health benefits. *Mar. Drugs* 2020, 18, 5856. [CrossRef], 6779. [CrossRef]
57. Trivedi, S.; Alshehri, M.A.; Aziz, A.T.; Panneerselvam, C.; Al-Aoh, H.A.; Maggi, F.; Sut, S.; Dall’Acqua, S. Insecticidal, antibacterial and dyes adsorbent properties of *Sargassum muticum* decorated nano-silver particles. *S. Afr. J. Bot.* 2021, 139, 432–441. [CrossRef]
58. Stalin Dhas, T.; Sowmiya, P.; Parthasarathy, K.; Natarajan, A.; Narendrakumar, G.; Kumar, R.; Samrot, A.V.; Riyaz, S.U.M.; Ganesh, V.K.; Barthick, V.; et al. In vitro antibacterial activity of biosynthesized silver nanoparticles against gram negative bacteria. *Inorg. Nano-Met. Chem.* 2022, 1–10. [CrossRef]
59. Selvaraj, P.; Neethu, E.; Rathika, P.; Jayaseeli, J.P.R.; Jermy, B.R.; AbdulAzeez, S.; Borgio, J.F.; Dhas, T.S. Antibacterial potentials of methanolic extract of marine alga. *Biocatal. Agric. Biotechnol.* 2020, 28, 101719. [CrossRef]
60. Thruchelvi, R.; Jayasree, P.; Mirunaalini, K. Synthesis of silver nanoparticle using marine red seaweed *Gelidiella acerosa*—A Complete study on its biological activity and its characterisation. *Mater. Today Proc.* 2021, 37, 1693–1698. [CrossRef]
61. Al-Dhabi, N.A.; Mohammed Ghilan, A.-K.; Arasu, M.V. Characterization of Silver Nanomaterials Derived from Marine *Streptomyces* sp. *Al-Dhabi-87* and Its In Vitro Application against Multidrug Resistant and Extended-Spectrum Beta-Lactamase Clinical Pathogens. *Nanomaterials* 2018, 8, 679. [CrossRef]
62. Rajeshkumar, S.; Nandhini, N.T.; Manjunath, K.; Sivaperumal, P.; Krishna Prasad, G.; Alothbi, S.S.; Roopan, S.M. Environment friendly synthesis copper oxide nanoparticles and its antioxidant, antibacterial activities using Seaweed (*Sargassum longifolium*) extract. *J. Mol. Struct.* 2021, 1242, 130724. [CrossRef]
63. Pacheco-Quito, E.M.; Ruiz-Caro, R.; Veiga, M.D. Carrageenan: Drug Delivery Systems and Other Biomedical Applications. *Mar. Drugs* 2020, 18, 583. [CrossRef]
136. Liu, C.; Fu, Y.; Li, C.-E.; Chen, T.; Li, X. Phycocyanin-functionalized selenium nanoparticles reverse palmitic acid-induced pancreatic β cell apoptosis by enhancing cellular uptake and blocking reactive oxygen species (ROS)-mediated mitochondria dysfunction. *J. Agric. Food Chem.* 2017, 65, 4405–4413. [CrossRef] [PubMed]

137. Kumar, P.; Yuvakkumar, R.; Vijayakumar, S.; Vaseeharan, B. Cytotoxicity of phloroglucinol engineered silver (Ag) nanoparticles against MCF-7 breast cancer cell lines. *Mater. Chem. Phys.* 2018, 220, 402–408. [CrossRef]

138. Mahalakshmi, M.; Kumar, P. Phloroglucinol-conjugated gold nanoparticles targeting mitochondrial membrane potential of human cervical (HeLa) cancer cell lines. *Spectrochim. Acta Part A Mol. Biomol. Spectrosc.* 2019, 219, 450–456. [CrossRef]

139. Khan, F.; Oh, D.; Chandika, P.; Jo, D.M.; Bamunarachchi, N.I.; Jung, W.K.; Kim, Y.M. Inhibitory activities of phloroglucinol-chitosan nanoparticles on mono- and dual-species biofilms of *Candida albicans* and bacteria. *Colloids Surf. B Biointerfaces* 2022, 211, 112307. [CrossRef] [PubMed]

140. Khan, F.; Kang, M.-G.; Jo, D.-M.; Chandika, P.; Jung, W.-K.; Kang, H.W.; Kim, Y.-M. Phloroglucinol-gold and-zinc oxide nanoparticles: Antibiofilm and antivirulence activities towards *Pseudomonas aeruginosa* PAO1. *Mar. Drugs* 2021, 19, 601. [CrossRef] [PubMed]

141. Jena, J.; Pradhan, N.; Dash, B.P.; Panda, P.K.; Mishra, B.K. Pigment mediated biogenic synthesis of silver nanoparticles using diatom *Amphora* sp. and its antimicrobial activity. *J. Saudi Chem. Soc.* 2015, 19, 661–666.

142. Chandika, P.; Khan, F.; Heo, S.-Y.; Kim, Y.-M.; Yi, M.; Jung, W.-K. Enhanced wound-healing capability with inherent antimicrobial activities of usnic acid incorporated poly (ε-caprolactone)/decellularized extracellular matrix nanofibrous scaffold. *Biomater. Adv.* 2022, 140, 213046. [CrossRef] [PubMed]

143. Abdelwahab, G.M.; Mira, A.; Cheng, Y.-B.; Abdelaziz, T.A.; Lahloub, M.F.I.; Khalil, A.T. Acetylcholine esterase inhibitory activity of green synthesized nanosilver by naphthopyrones isolated from marine-derived *Aspergillus niger*. *PLoS ONE* 2021, 16, e0257071. [CrossRef]

144. Dai, S.; Wang, B.; Song, Y.; Xie, Z.; Li, C.; Li, S.; Huang, Y.; Jiang, M. Astaxanthin and its gold nanoparticles mitigate cadmium toxicity in rice by inhibiting cadmium translocation and uptake. *Sci. Total Environ.* 2021, 786, 147496. [CrossRef] [PubMed]

145. Manivasagan, P.; Khan, F.; Hoang, G.; Mondal, S.; Kim, H.; Doan, V.H.M.; Kim, Y.-M.; Oh, J. Thiol chitosan-wrapped gold nanoshells for near-infrared laser-induced photothermal destruction of antibiotic-resistant bacteria. *Carbohydr. Polym.* 2019, 225, 115228. [CrossRef] [PubMed]